首页 > 市场调查报告书 > 医疗设备

药物递输设备

市场调查报告书

商品编码

1634171

全球干粉吸入器 (DPI) 市场 - 2025 - 2033

Global Dry Powder Inhalers (DPIs) Market - 2025 - 2033

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球干粉吸入器市场规模达到10.2亿美元，预计2033年将达到15.6亿美元，2025-2033年预测期间复合年增长率为5.1%。

干粉吸入器 (DPI) 是将粉状药物直接注入肺部的医疗设备。它们通常用于治疗气喘和慢性阻塞性肺病（COPD）等呼吸系统疾病。干粉吸入器的特征是其呼吸活化机制，确保只有当患者透过吸嘴深用力吸气时药物才会释放。与利用推进剂给药的计量吸入器 (MDI) 不同，DPI 利用患者的吸入将粉末状药物分散成气雾剂形式，从而到达肺部狭窄的气道。

对干粉吸入器的需求不断增长是预测期内推动市场的驱动因素。例如，呼吸系统疾病的日益流行增加了对干粉吸入器的需求，因为它们在慢性呼吸系统疾病的治疗和管理中发挥着至关重要的作用。例如，根据美国气喘和过敏基金会的数据，美国有近 2800 万人患有气喘。这相当于大约每十二个人中就有一个。在美国，气喘影响着 18 岁及以上的近 2,300 万人。女性比男性更容易患气喘。气喘影响约 11.0% 的成年女性和 6.8% 的男性。它是青少年的主要慢性疾病。目前，约有 490 万名 18 岁以下儿童患有气喘。

市场动态：

驱动程式和限制

对干粉吸入器的需求不断增加

对干粉吸入器的需求不断增长预计将成为全球干粉吸入器市场成长的重要因素。呼吸系统疾病病例数量的增加、药物输送比传统吸入器更方便、技术进步、研究经费增加以及认识的提高增加了对干粉吸入器的需求并推动了市场。

随着慢性阻塞性肺病、气喘和鼻窦炎等慢性呼吸道疾病在全球范围内变得越来越普遍，干粉吸入器的需求不断增加，因为它在支气管炎、慢性阻塞性肺病和哮喘等慢性呼吸道疾病的管理和控制中发挥着重要作用。例如，根据卫生与公共服务部的数据，全球每 20 人就有 1 人患有慢性呼吸道疾病 (CRD)。东亚和南亚的 CRD 死亡率最高。中低和低社会人口指数 (SDI) 国家的 CRD 死亡率年龄标准化率最高。关于慢性呼吸道疾病 (CRD) 的新研究结果显示，它是全球第三大死因，导致全球约 400 万人死亡。这些人中约 60%（约 2.62 亿）被诊断出患有气喘，使其成为最常见的 CRD。自 1990 年以来，CRD 新病例数量增加了 49.0%，这主要是由于人口增长。另一方面，年龄标准化发生率下降了 5.3%。

与传统吸入器相比，干粉吸入器的药物输送简单性和使用者友善性增加了需求。与典型吸入装置相比，DPI 的主要优点之一是能够将药物直接输送到肺部，而无需推进剂或液体。这项属性不仅提高了患者的依从性，也减少了对环境的影响。 DPI 旨在用户友好且便于携带，使其成为需要持续治疗慢性呼吸系统疾病的患者的合适选择。 DPI 的简便性和有效性预计将提高其在医疗保健专业人员和患者中的接受度。

此外，DPI 设计和配方的技术进步正在推动市场扩张。诸如基于胶囊的设备等创新技术可减少水分暴露，从而提高可靠性和性能，从而提高患者满意度和依从性。将智慧技术融入吸入器（例如监控使用情况的感测器），为改善治疗结果和患者参与创造了新的前景。这些进步不仅满足了现有患者的需求，也吸引了以前可能不愿意采用吸入疗法的新用户。

用于开发和改进干粉吸入器 (DPI) 的资金对于加强呼吸护理和增加有效治疗的机会至关重要。例如，2023 年 10 月，美国食品药物管理局 (FDA) 资助澳洲研究人员 100 万澳元（687,000 美元），用于开发改进的干粉吸入器测试程序。该计划将使吸入器，特别是通用吸入器设备的开发更加有效，目标是为全球气喘患者提供负担得起的吸入器。

与使用干粉吸入器相关的副作用

与使用干粉吸入器相关的副作用等因素预计将阻碍全球干粉吸入器市场。一个主要问题是鹅口疮的流行，这是一种真菌疾病，当粉状药物沉积在口腔或喉咙时就会发生。根据研究，透过 DPI 使用吸入性皮质类固醇会增加鹅口疮的发生率，尤其是较大剂量时。患者可能会出现口腔不适、喉咙刺激和声音沙哑等症状，这可能会影响他们继续使用这些设备的意愿。此外，有些人可能对乳糖敏感，乳糖是许多 DPI 中常见的载体，可能会导致乳糖不耐受患者胃肠道不适或过敏反应。

除了局部副作用外，透过 DPI 持续给予皮质类固醇可能会产生全身性副作用。随着时间的推移，高剂量可能会导致骨质疏鬆症、糖尿病和其他全身性疾病等问题。这些潜在的健康危害可能会增加患者对长期使用 DPI 的焦虑，并导致不遵守规定的治疗。

Dry powder inhalers (DPIs) are medical devices that administer powdered drugs directly into the lungs. They are generally used to treat respiratory disorders like asthma and chronic obstructive pulmonary disease (COPD). A dry powder inhaler is distinguished by its breath-activated mechanism, which ensures that the drug is only released when the patient inhales deeply and forcefully via the mouthpiece. Unlike metered-dose inhalers (MDIs), which utilize propellants to administer medication, DPIs employ the patient's inhalation to disperse the powdered medication into an aerosol form that can reach the narrow airways of the lungs.

The increasing demand for dry powder inhalers is the driving factor that drives the market over the forecast period. For instance, the increasing prevalence of respiratory diseases increases the demand for dry powder inhalers since they play a vital role in the treatment and management of chronic respiratory diseases. For instance, according to the Asthma and Allergy Foundation of America, Nearly 28 million people in the United States suffer from asthma. This equates to around one in every twelve people. Asthma affects almost 23 million persons in the United States, aged 18 and older. Asthma is more frequent in women than men. Asthma affects around 11.0% of female adults and 6.8% of male people. It is a major chronic disease among youngsters. Currently, around 4.9 million children under the age of 18 have asthma.

Market Dynamics: Drivers & Restraints

Increasing demand for dry powder inhalers

The increasing demand for dry powder inhalers is expected to be a significant factor in the growth of the global dry powder inhalers market. The increasing number of cases of respiratory disorders, ease of drug delivery than traditional inhalers, technological advancements, increased research funds, and increasing awareness increase the demand for dry powder inhalers and drive the market.

As chronic respiratory conditions like COPD, asthma, and sinusitis become more prevalent globally, the demand for dry powder inhalers increases as it plays an important role in the management and control of chronic respiratory diseases like bronchitis, COPD, and asthma. For instance, according to the Department of Health & Human Services, 1 in 20 people globally suffers from chronic respiratory disease (CRD). East Asia and South Asia had the highest rates of CRD mortality. Low-middle and low Socio-demographic Index (SDI) countries had the highest age-standardized rates of CRD deaths. New findings on chronic respiratory disease (CRD) now show it is the third leading cause of death globally, accounting for approximately 4 million deaths worldwide. Asthma was diagnosed in approximately 60% of these people (approximately 262 million), making it the most common CRD. Since 1990, the number of new cases of CRDs has increased by 49.0%, owing primarily to population growth. The age-standardized incidence rate, on the other hand, has decreased by 5.3%.

The ease of drug delivery and user-friendly nature of dry powder inhalers to traditional inhalers increase the demand. One of the primary advantages of DPIs over typical inhalation devices is their ability to deliver medication directly to the lungs, eliminating the need for propellants or liquids. This attribute not only improves patient compliance but also reduces environmental effects. DPIs are intended to be user-friendly and portable, making them a suitable option for patients who require ongoing treatment for chronic respiratory disorders. The ease and effectiveness of DPIs are projected to drive their acceptance among both healthcare professionals and patients.

Furthermore, technological advancements in DPI design and formulation are driving market expansion. Innovations like capsule-based devices that decrease moisture exposure improve dependability and performance, resulting in higher patient satisfaction and adherence. The incorporation of smart technology into inhalers, such as sensors that monitor usage, creates new prospects for improving treatment outcomes and patient participation. These advancements not only meet existing patient needs but also attract new users who may have previously been unwilling to adopt inhalation therapy.

The funding allocated for the development and improvement of dry powder inhalers (DPIs) is critical to enhancing respiratory care and increasing access to effective therapies. For instance, in October 2023, The US Food and Drug Administration (FDA) funded Australian researchers $AU1 million ($US687,000) to develop improved dry powder inhaler testing procedures. The initiative will enable more effective development of inhalers, particularly generic inhaler devices, with the goal of providing access to affordable inhalers for asthma patients across the globe.

Side effects associated with the usage of dry powder inhalers

Factors such as side effects associated with the usage of dry powder inhalers are expected to hamper the global dry powder inhalers market. One major issue is the prevalence of oral thrush, a fungal disease that can develop when powdered drugs settle in the mouth or throat. According to research, using inhaled corticosteroids via DPIs increases the incidence of oral thrush, especially at larger doses. Patients may endure symptoms such as discomfort in the mouth, throat irritation, and hoarseness, which can influence their willingness to continue using these devices. Furthermore, some people may be sensitive to lactose, a frequent carrier found in many DPIs, which can cause gastrointestinal discomfort or allergic responses in lactose-intolerant patients.

In addition to local side effects, there are concerns regarding systemic side effects from continuous corticosteroid administration via DPIs. High doses over time might result in problems such as osteoporosis, diabetes, and other systemic disorders. These potential health hazards can increase patient anxiety over long-term DPI use and lead to nonadherence to prescribed therapy.

Segment Analysis

The global dry powder inhalers market is segmented based on product type, dosage, indication type, distribution channel, and region.

The multi-dose dry powder inhalers segment is anticipated to dominate the global dry powder inhalers market owing to its cost-effectiveness, longer shelf life, ease of use, strategic partnerships, and increasing prevalence of respiratory disorders.

One of the primary benefits of MDPIs is their cost-effectiveness. These devices often have a longer shelf life and less pharmaceutical waste, making them cost-effective for both patients and healthcare systems. The combination of price and ease of use makes MDPIs a popular alternative, particularly as healthcare providers prioritize effective and efficient respiratory disease treatment solutions.

Technological developments will also play an important part in the expansion of the multi-dose segment. Smart inhalers, which combine digital health solutions, improve patient involvement and treatment adherence. These devices can monitor usage patterns, remind patients to take their prescriptions and provide feedback on inhaling practices, ultimately enhancing treatment outcomes. As healthcare systems increasingly adopt digital health technology, MDPIs are likely to gain from greater integration into patient care initiatives.

For instance, according to the American Lung Association, COPD affects 11.7 million adults, resulting in hundreds of thousands of emergency department visits and tens of billions of dollars in healthcare expenses each year. Moreover, according to the Cystic Fibrosis Foundation, Cystic fibrosis affects about 40,000 children and adults in the United States (an estimated 105,000 people have been diagnosed with the disease in 94 countries), and it can affect people of any ethnic background. So, multi-dose dry powder inhalers play an important role in the treatment and management of chronic respiratory disorders. The increasing number of chronic respiratory disorders upsurges the demand for multi-dose dry powder inhalers.

The strategic partnerships took place to enhance the quality and efficiency of the multi-dose dry powder inhalers. For instance, in May 2023, H&T Presspart, a global supplier of drug delivery devices and components, announced a collaborative partnership with Hovione, a specialist integrated CDMO and leader in spray drying and particle engineering, to develop the new Sunrise high-performance dry powder inhaler technology platform. H&T Presspart's revolutionary Sunriser technology is adaptable enough to meet the challenges of both traditional carrier-based and spray-dried tailored formulations, as well as an expanding range of dry powder formulations, new particle engineering, and powder processing technologies. As part of the collaborative development agreement, H&T Presspart will continue to develop and manufacture the Sunriser device.

Geographical Analysis

The dominance of the North American market in the global dry powder inhaler market is due to various factors such as advanced healthcare infrastructure, high prevalence of respiratory diseases, strategic partnerships, technological advancements, product launches, and approvals, and increasing adoption of innovative medical technologies.

One of the primary factors contributing to North America's dominance in the dry powder inhaler market is technological improvements that improve the functionality and user experience of dry powder inhalers. Recent advances have focused on enhancing device usability, drug delivery accuracy, and patient adherence. Many recent DPI advancements include integrated dose counters and audible feedback mechanisms that assist patients in receiving the exact dosage while also serving as medication adherence reminders. Furthermore, advances in materials and design have resulted in the creation of lightweight, portable inhalers that are easier for patients to transport and use on the go.

For instance, in February 2024, Catalent, Inc., a global leader in enabling the development and supply of better therapies for patients, completed remodeling and device advancement to its capsule filling of Dry Powders for Inhalation and capsule blistering suites in Boston, MA, to handle strong pharmaceuticals. Catalent is currently the CDMO with the most GMP capacity for capsule spray-dried and carrier-based inhaled powders, due to recent enhancements that include more capacity for both development and commercial spray drying.

The increasing prevalence of respiratory disorders in this region increases the demand for dry powder inhalers. For instance, according to health.gov, respiratory diseases affect millions of people in the United States. More than 25 million people in the United States have asthma. Strategies to reduce environmental triggers and make sure people get the right medications can help prevent hospital visits for asthma. In addition, more than 16 million people in the United States have COPD (chronic obstructive pulmonary disease), which is a major cause of death.

Asia Pacific is growing at the fastest pace in the global dry powder inhalers market

The Asia Pacific region is emerging as the fastest-growing market for dry powder inhalers, owing to a combination of demographic trends, increased healthcare investment, recent launches, and an increasing prevalence of respiratory diseases.

The increasing prevalence of respiratory diseases is one of the factors that drive the market in this region. For instance, according to The International Primary Care Respiratory Group, India has one of the highest rates of chronic respiratory illness. India accounts for 15.69% of worldwide chronic respiratory diseases, whereas 30.28% of all global deaths from chronic respiratory diseases occur in India. India has the world's greatest number of COPD (Chronic Obstructive Pulmonary Disease) cases, totaling 55.23 million. India has the second-highest number of COPD-related deaths globally, accounting for almost 0.85 million.

There are recent product launches of anesthesia devices in this region. For instance, in 2023, Aptar Pharma launched Orbital Dry Powder Inhaler (DPI), a revolutionary device for delivering high-payload powder medication formulations directly to the lungs. This innovative inhaler technology stands out for its ability to give accurate and consistent dosing over several inhalations, which improves patient compliance and minimizes the risk of coughing during administration. The Orbital DPI is adaptable to both single-use and reuse applications, making it suitable for a wide range of therapeutic purposes.

Competitive Landscape

The major global players in the global dry powder inhalers market include AstraZeneca, Boehringer Ingelheim International GmbH, Vectura Group Ltd, Otsuka Pharmaceutical Co., Ltd., Respira Therapeutics Inc., CHIESI Farmaceutici S.p.A., Cipla, GlaxoSmithKline plc., Hovione, Mankind Pharma among others.

Emerging Players

Merxin Ltd, Aerovate Therapeutics, and PULMATRiX, Inc. among others

Key Developments

In November 2024, Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announced that it has signed an exclusive collaboration agreement with Cambridge Healthcare Innovations (CHI) to commercialize and promote its Quattrii Dry Powder Inhaler (DPI) platform.
In April 2024, Berry Global, a leader in the design, development, and manufacturing of patient-centered healthcare solutions, recently introduced the BerryHaler, a dual chamber, dry powder inhaler (DPI) with a dose counter that improves patient access to and supports the effective delivery of combination drugs.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global dry powder inhalers market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Dosage
3.3. Snippet by Indication Type
3.4. Snippet by Distribution Channel
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.2. Increasing Demand for Dry Powder Inhalers
- 4.1.3. Restraints
- 4.1.4. Side Effects Associated with The Usage of Dry Powder Inhalers
- 4.1.5. Opportunity
- 4.1.6. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Capsule Based Device*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Blister Based Devices
6.4. Reservoir/Cartridge Based Devices
6.5. Others

7. By Dosage

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
- 7.1.2. Market Attractiveness Index, By Dosage
7.2. Single-Dose Dry Powder Inhalers*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Multi-Dose Dry Powder Inhalers

8. By Indication Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
- 8.1.2. Market Attractiveness Index, By Indication Type
8.2. Bronchitis*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. COPD
8.4. Asthma
8.5. Others

9. By Distribution Channel

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. The U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. UK
  - 10.3.7.3. France
  - 10.3.7.4. Italy
  - 10.3.7.5. Spain
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication Type
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. AstraZeneca *
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Boehringer Ingelheim International GmbH
12.3. Vectura Group Ltd
12.4. Otsuka Pharmaceutical Co., Ltd.
12.5. Respira Therapeutics Inc.
12.6. CHIESI Farmaceutici S.p.A.
12.7. Cipla
12.8. GlaxoSmithKline plc.
12.9. Hovione
12.10. Mankind Pharma

LIST NOT EXHAUSTIVE